in vitro News and Research

RSS

Corgenix Medical enters development agreement wth NIH

Corgenix Medical Corporation has announced it has entered into a corporative research and development agreement (CRADA) with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

18 Dec 2007

Treatment with secretoneurin reduces injury to the brain following stroke

Stroke is the term used to describe deteriorating brain function due to either the leaking of blood vessels (hemorrhage) or oxygen deprivation (ischemia) in the brain.

14 Dec 2007

Cancer cell line developed that is resistant to new cancer therapy

A cancer cell line that is resistant to one of the newest classes of cancer treatments has been developed by researchers who already are using it to determine what else to give patients when this happens.

12 Dec 2007

Lipids in the brain an important factor for Alzheimer's disease

As the most common form of dementia in the Western world, Alzheimer's disease carries enormous implications for our ageing society.

10 Dec 2007

Safe and effective therapy discovered for patients with protein-losing enteropathy

Researchers at the Burnham Institute for Medical Research (Burnham Institute) have developed the first model to study intestinal protein leakage in mice, allowing the team to control and replicate both genetic deficiencies and environmental damages in an in vivo setting.

10 Dec 2007

New understanding of biological effects of alcohol on genes within cells

Alcohol triggers the activation of a variety of genes that can influence the health and activity of brain cells, and new research from Weill Cornell Medical College in New York City sheds light on how that process occurs.

10 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007

sLRP1-alpha provides relief from neuropathic pain

Injury to peripheral nerves (the causes of which include shingles, HIV-AIDS, toxins, alcoholism, repetitive motion disorders, surgery, and cancer) causes neuropathic pain, which differs from ordinary pain and is usually perceived as a steady burning, pins and needles, electric shock sensations, and/or tickling.

4 Dec 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

First chemical evidence of a sperm recognition system in the oviducts of pigs

Adding another layer of competition to the mating game, scientists are reporting possible biochemical proof that the reproductive system of female mammals can "sense" the presence of sperm and react to it by changing the uterine environment.

19 Nov 2007

CD200 stifles anti-tumor immunity

The prognosis for individuals with metastatic melanoma (MM) is not good. Therapeutic strategies to enhance the immune response have some clinical benefit; however, most patients eventually succumb to progressive disease, in part because their immune cells known as dendritic cells (DCs) fail to sustain an effective antitumor T cell immune response.

16 Nov 2007

Freeze-dried grape powder blocks genes linked to colon cancer

Low doses of freeze-dried grape powder inhibit genes linked to the development of sporadic colorectal cancer, University of California, Irvine cancer researchers found.

15 Nov 2007

Breakthrough innovation for high sensitivity TB and Malaria diagnostics

At this year's 39th World Forum for Medicine in Dusseldorf (MEDICA, November 14-17), Partec, a globally leading developer, manufacturer and provider of dedicated diagnostic solutions in the response to HIV/AIDS, Tuberculosis and Malaria is presenting a breakthrough innovation for high sensitivity TB and Malaria diagnostics in low- and middle-income countries.

15 Nov 2007

EDMA calls for empowering people with diabetes

Type 2 diabetes and its complications are frequently diagnosed too late and the complications are often detected only at the time of diagnosis, concludes the European Parliament in its 2006 Written Declaration on Diabetes.

14 Nov 2007

Implanting myoblasts may improve severe urinary incontinence

Estimates are that up to 70 million people worldwide may be suffering from severe urinary incontinence. A major cause of urinary incontinence is a deficiency of the urethral sphincter muscle, often associated with trauma during child birth, resulting from prostate surgery, or due to aging.

14 Nov 2007

Research looks at how environment inside a living cell affects protein structure

The syrupy soup of proteins, ribosomes and membranes inside a living cell is so tightly packed it may increase the structural content of proteins by as much as 25 percent, according to new research from Rice University and the University of Houston (UH).

13 Nov 2007